Camurus AB

Quick facts

Phase 3 pipeline

• CAM2029 · Psychiatry / Addiction Medicine
  CAM2029 is a long-acting buprenorphine formulation designed to provide sustained opioid receptor agonism for opioid use disorder treatment.
• Lanreotide ATG · Oncology / Endocrinology
  Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.

Phase 2 pipeline

• leuprolide acetate FluidCrystal® injection depot
• octreotide FluidCrystal® injection depot

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Camurus AB portfolio CI brief
• Camurus AB pipeline updates RSS